SillaJen's BAL0891 Wins FDA Orphan Drug Designation for Acute Myeloid Leukemia
核心洞察
SillaJen (搜索)'s first-in-class cancer candidate BAL0891 received U.S. FDA Orphan Drug Designation for the treatment of acute myeloid leukemia (搜索) (AML).
BAL0891 simultaneously inhibits TTK (搜索) and PLK1 (搜索), two proteins involved in cancer cell division, and is currently in a global Phase 1 trial for solid tumors and blood cancers.
The designation provides research grant eligibility, a 25% tax credit on U.S. clinical trial costs, priority review support, and waiver of new-drug application fees.
SillaJen (搜索) announced on the 25th that its next-generation oncology pipeline candidate BAL0891 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (搜索) (AML).
BAL0891 is a first-in-class anti-cancer drug candidate that simultaneously targets TTK (搜索) and PLK1 (搜索), key proteins involved in the cancer cell division process. The drug is currently in global Phase 1 clinical trials for both solid tumors and hematologic malignancies.
A Dual-Targeting Mechanism for Resistant Disease
Acute myeloid leukemia (搜索) is a blood cancer in which hematopoietic cells in the bone marrow that produce white blood cells transform into cancer cells and proliferate rapidly. The disease is difficult to diagnose early because it presents no distinct symptoms in its initial stages, and it is characterized by rapid disease progression.
Existing AML treatments have primarily relied on intensive chemotherapy or hematopoietic stem cell transplantation, which have been criticized for their side effects and risk of recurrence. More recently, therapies targeting specific genes or proteins have emerged, but they carry the limitation that drug resistance can develop during the course of treatment.
According to the company, BAL0891's mechanism of simultaneously inhibiting TTK (搜索) and PLK1 (搜索), both of which are involved in cancer cell division, positions it as a potential new treatment alternative for AML patients who have developed resistance to existing therapies. By targeting both proteins at once, SillaJen (搜索) aims to offer a new option for patients who have developed resistance to existing treatments.
Orphan Drug Designation Benefits
The FDA Orphan Drug Designation program is designed to accelerate the development of treatments for rare diseases affecting fewer than 200,000 patients in the United States. With this designation, SillaJen (搜索) has secured eligibility to apply for FDA clinical research grant funding during the development of BAL0891. The company will also benefit from a 25% tax credit on U.S. clinical trial costs, FDA clinical trial protocol consultation and expedited review support, and waiver of new drug application filing fees.
If the drug ultimately receives marketing approval, SillaJen (搜索) would in principle secure seven years of market exclusivity in the United States for the same drug and indication.
Company Outlook
"Receiving Orphan Drug Designation at this early clinical stage suggests that the medical importance and potential of BAL0891 have been recognized to a certain degree. Building on this achievement, we will do our utmost to deliver even more positive results in the remaining clinical milestones ahead," a SillaJen (搜索) representative stated.
A SillaJen (搜索) official added that being designated an orphan drug at an early stage of clinical development is significant because it confirms BAL0891's development potential, and that the company would carry out follow-up trials without delay.